Close this search box.

Does ICER’s Model Work for Rheumatoid Arthritis Treatments?

The Institute for Clinical and Economic Review’s newest cost-effectiveness report underscores just how far economic modeling sometimes diverges from patients’ reality, explained the Institute for Patient Access in a February 17 letter.  The report analyzes rheumatoid arthritis treatments’ value by modeling expenses for simulated patients over a lifetime on certain treatments.